文献速递系统性红斑狼疮

系统性红斑狼疮患者10年临床缓解与低疾病活动度结局

Clinical Remission and Low Disease Activity Outcomes Over 10 Years in Systemic Lupus Erythematosus.
PubMed 文献 · Arthritis Care Res (Hoboken) · 2019-05-10

该研究基于多伦多狼疮诊所起始队列中267例随访≥10年的患者,评估长期(10年)持续临床缓解与持续低疾病活动度(LDA)的结局。结果显示27例(10.1%)达到持续临床缓解,48例(18%)达到持续LDA,两组在10年后累积损伤、复发率及随访期间死亡率相当,持续LDA组76%的随访时间处于完全缓解。作者认为持续LDA可作为SLE可接受的达标治疗结局。

要点

  • 267例随访≥10年的SLE患者中,27例(10.1%)达到持续临床缓解,48例(18%)达到持续LDA。
  • 两组在10年后累积损伤、复发率及随访期间死亡率相当。
  • 持续LDA组SLE处于完全缓解的时间占随访时间的76%。

核心结论

  • 持续临床缓解和持续LDA分别见于10.1%和18%的患者,长期结局相当,使持续LDA成为SLE可接受的达标治疗结局。

研究设计与样本

  • 多伦多狼疮诊所起始队列研究,纳入随访至少10年且相邻访视间隔不超过18个月的患者,共267例。
  • 持续临床缓解定义为入组前5年内达到SLEDAI-2K评分0分(排除血清学)并维持至少10年;持续LDA定义为SLEDAI-2K评分≤2分(排除血清学)且同样满足时间限制。

主要发现

  • 267例患者中27例(10.1%)达到持续临床缓解,48例(18%)达到持续LDA。
  • 两组在任何时间点的人口学、临床和免疫学变量均无差异。
  • 达到缓解的患者入组时平均泼尼松剂量更高,而持续LDA患者在入组时和10年后使用抗疟药更频繁。
  • 10年后累积损伤和复发率以及整个随访期间的死亡率在两组间相当。
  • 持续LDA组SLE处于完全缓解的时间占随访时间的76%。

关键数值与推荐

  • 持续临床缓解:入组前5年内达到SLEDAI-2K评分0分(排除血清学)并维持至少10年。
  • 持续LDA:SLEDAI-2K评分≤2分(排除血清学),同样在入组前5年内达到并维持至少10年。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: A recent study conducted by our clinical group demonstrated that low disease activity (LDA), defined as a clinical Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) score ≤2, maintained for 12 months, confers the same risk for damage accrual as complete remission after 2 years. The aim of the present study was to assess the validity of these findings in the long term (10 years). METHODS: Patients in the inception cohort of the Toronto Lupus Clinic, who had a minimum follow-up of 10 years and no interval >18 months between consecutive visits, were included in the analysis. Prolonged clinical remission was defined based on a SLEDAI-2K score of 0 (serology excluded), achieved within the first 5 years of enrollment and maintained for ≥10 years. Prolonged LDA was defined as SLEDAI-2K score ≤2 (serology excluded) with the same time frame restrictions. RESULTS: Of 267 patients, 27 (10.1%) achieved prolonged clinical remission and 48 (18%) attained prolonged LDA. There were no differences regarding demographic, clinical, and immunologic variables at any time. The mean prednisone dose at enrollment was higher in patients in whom remission was achieved, while patients with prolonged LDA were taking antimalarials more frequently, both at enrollment and after the 10-year time period. Cumulative damage and flare rate after 10 years, and mortality throughout follow-up were comparable. SLE in patients in the prolonged LDA group was in complete remission for 76% of the follow-up time. CONCLUSION: Prolonged clinical remission and LDA were demonstrated in 10.1% and 18% of our patients, respectively, and comparable outcomes were demonstrated in the long term, rendering sustained LDA an acceptable treat-to-target outcome in SLE.

来源:Arthritis Care Res (Hoboken),查看原文。版权归原作者所有。

引用

  1. Tselios K, Gladman DD, Touma Z, et al. Clinical Remission and Low Disease Activity Outcomes Over 10 Years in Systemic Lupus Erythematosus. Arthritis Care Res (Hoboken). 2019. PMID: 30055090. doi:10.1002/acr.23720

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。